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BIDIRECTIONAL REGULATION OF YAP AND ALDH1A1 
 
Breast cancer is the second leading cause of cancer death for women in the United 
States. Approximately, 1 in 5 women will recur with cancer within 10 years of 
completing treatment and recent publications have suggested that breast cancer stem cells 
confer resistance to therapy. These reports highlight aldehyde dehydrogenase 1A1 
(ALDH1A1) and Yes-associated protein (YAP) as a biomarker and key mediator of the 
stem cell phenotype respectively. To further understand how YAP and ALDH1A1 
facilitate chemoresistance, this study investigated how ALDH1A1 specific inhibition 
affected YAP activity and growth of basal-like breast cancer cells, which are enriched in 
cancer stem cells. Intriguingly, attenuation of growth by ALDH1A1 inhibition was 
observed when cells were plated on a reconstituted basement membrane. Further, the 
inhibition of cell growth correlated with cytosolic retention of YAP and a reduction in 
YAP signaling. In a complementary analysis, the overexpression of YAP correlated with 
an increased level of ALDH1A1 transcript. Results from this study indicate a novel 
mechanism by which basal-like breast cancer cells utilize YAP to maintain the stem cell 
phenotype and also suggest ALDH1A1 as a potential therapeutic target for breast cancer 
therapy. 
 
Clark Wells, PhD, Chair 
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INTRODUCTION 
 
Breast cancer is the second leading cause of cancer death for women in the United 
States (American Cancer Society, 2013). Currently, around 60,000 women develop non-
invasive tumors per year and the rate of incidence increases until the age of 50 where 
then a decline is observed (Table 1 and Figure 1)  (American Cancer Society, 2013). 
Sadly however, nearly 240,000 women develop invasive breast cancer per year and the 
rate of mortality steadily increases with age (Table 1 and Figure 1) (American Cancer 
Society, 2013). Treatments include surgery, radiation therapy, and chemotherapy 
(American Cancer Society, 2013), but one in five women will have recurrence of breast 
cancer within 10 years of completing treatment (A. M. Brewster et al., 2008). While the 
biological mechanism underlying cancer recurrence is very poorly understood, recent 
research suggests that subpopulations of breast cancer stem cells survive therapy and 
rapidly promote metastasis and invasion (A. Grosse-Wilde et al., 2015; M. Luo et al., 
2015; M. Wang, Y. Wang, & J. Zhong, 2015).  
Recent studies have linked cells that have undergone an epithelial to 
mesenchymal transitions (EMT) to having a stem cell identity (A. Grosse-Wilde et al., 
2015). During EMT, epithelial markers such as E-cadherin, Claudins and Occludins are 
lost while proteins that mediate the mesenchymal cell phenotype such as Snail, Twist, 
and Slug are upregulated (Figure 2) (G. Barriere, P. Fici, G. Gallerani, F. Fabbri, & M. 
Rigaud, 2015). Claudins and Occludins are critical for maintaining cellular tight junctions 
while E-Cadherin is the main strand protein at adherence junctions (Berk A Lodish H, 
Zipursky SL, et al. , 2000). Together these proteins are essential for maintaining 
intercellular attachments to make up an epithelial sheet or duct while maintaining a 
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physical barrier between the internal and external environment. Conversely, Snail, Twist, 
and Slug function as transcription factors that suppress the expression of cadherin (H. 
Peinado, F. Portillo, & A. Cano, 2004) and facilitate the molecular events involved in 
cellular motility. 
The molecular events that promote cell proliferation in situ must also be 
considered when attempting breast cancer therapies. Considerable effort has gone into 
understanding and developing drugs against the human epidermal growth factor receptor 
2 (EGFR2) (J. Zekri et al., 2015) and the estrogen receptor (ER) (M. Yamamoto-Ibusuki, 
M. Arnedos, & F. Andre, 2015). Unfortunately, while coupling these targeted approaches 
with standard chemotherapy and radiation improves outcomes, the high frequency of 
recurrence of the cancer still remains. This justifies new approaches where the role of 
breast cancer stem cells is one of the most promising avenues for developing new 
therapeutics. 
Stem cells are generally defined as self-renewing cells that have the pluripotent 
potential to regenerate any particular tissue (Berk A Lodish H, Zipursky SL, et al., 
2000b). For almost six decades, the concept was that mammary tissue stem cells 
(MaSCs) reside within the heterogeneous architecture of the tissue and facilitate the 
cycles of regeneration and regression with successive pregnancies. (A. Skibinski & C. 
Kuperwasser, 2015). This theory was validated in 2006 when Shackleton et al. and Stingl 
et al. demonstrated in a murine model that MaSCs, isolated by fluorescent-activated cell 
sorting (FACS), are essential for lobule outgrowth. While their markers of CD49 and 
CD24 for isolating stem cells have recently been replaced by CD44 and CD24, the 
original work illustrates the significance of MaSCs in the initiation of the breast cancer. 
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Subsequent analyses have identified aldehyde dehydrogenase 1A1 (ALDH1A1) 
as an additional high value biomarker for cancer stem cells (Y. Liu et al., 2014; Y. Luo et 
al., 2012; I. Olmez, W. Shen, H. McDonald, & B. Ozpolat, 2015; S. Wu et al., 2015). 
High expression of ALDH1A1 is also correlated with a poor clinical outcomes as 
evidenced by one report which found a 26% increase in risk per Kaplan-Meir curve 
analysis (S. Wu et al., 2015). ALDH1A1 belongs to the aldehyde dehydrogenase (ALDH) 
superfamily of enzymes which collectively catalyze the oxidation of aldehydes to their 
corresponding carboxylic acids (B. Jackson et al., 2011). ALDH1A1 converts 
retinaldehyde to retinoic acid (RA), the key ligand for the retinoic acid receptor (RAR). 
Because RAR is important for eukaryotic gene expression (Berk A Lodish H, Zipursky 
SL, et al., 2000a) and promotes the differentiation of embryonic stem cells (J. H. Chuang, 
L. C. Tung, & Y. Lin, 2015), ALDH1A1 has been proposed to inhibit differentiation by 
depleting RA. All translational efforts have focused on inhibiting ALDH1A1 to combat 
alcohol dependence (A. Yoshida, V. Dave, R. J. Ward, & T. J. Peters, 1989) but last year, 
inhibition of ALDH1A1 was shown to prevent the formation ovarian spheroids in vitro 
(S. Condello et al., 2014). This strongly implicated ALDH1A1 in the function of ovarian 
cancer stem cells. Thus, the importance of ALDH1A1 in other cancer types, such as 
breast, that rely on stem cells for growth and recurrence needs to be considered. 
Two related factors that have been implicated in cancer stem cell renewal are the 
Yes-associated protein (YAP) and Tafazzin (TAZ).  These structurally similar 
transcriptional co-activators are tightly regulated by the HIPPO Tumor Suppressor 
Pathway (M. Cordenonsi et al., 2011) in growth-arrested cells. Canonically, HIPPO 
signaling is characterized by the activation of the mammalian STE20-like (MST) 1/2 
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protein kinases that phosphorylate the large tumor suppressors (LATS) 1/2 whose 
downstream target is YAP (Y. Hao, A. Chun, K. Cheung, B. Rashidi, & X. Yang, 2008), 
the transcription co-activator of key pro-growth factors (J. Avruch et al., 2012). 
Interestingly, the HIPPO pathway responds to anti-growth cellular signals including: 
intercellular contacts, lack of growth factors, and metabolic stress (S. Piccolo, S. Dupont, 
& M. Cordenonsi, 2014). More recently in the context of stem cells, it has been suggested 
that YAP is regulated by metabolic states such as aerobic glycolysis (E. Enzo et al., 
2015), but the mechanism by which this occurs remains to be determined. 
Several cell lines have been developed for studying different subtypes of breast 
cancer. For example, cell lines such as MCF7 (ER+/PR+/HER-) and SKBR3 (ER-/PR-
/HER+) are of luminal origin, whereas MDA-MB-468 (ER-/PR-/HER-) cells are derived 
from the basal epithelia (R. M. Neve et al., 2006). These cell lines are an essential 
component of drug discovery, especially in recent work focusing on the response to 
chemotherapy of basal-like triple negative cell lines (B. T. Hennessy et al., 2009). 
Although, ALDH1A1 expression has been implicated as a cancer stem cell 
marker (Y. Liu et al., 2014; Y. Luo et al., 2012; I. Olmez et al., 2015; S. Wu et al., 2015), 
its functional significance in this context remains to be determined. Given that triple-
negative breast cancers are a disease without a molecular target (F. Tomao et al., 2015), 
strategies for targeting the disease are needed as evidenced by Table 1 and Figure 1. This 
investigation directly addresses this point by investigating the impact of selective 
inhibition of ALDH1A1 on basal like breast cancer growth and simultaneously the role of 
YAP inducing and mediating ALDH1A1 function.   
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Table 1. Estimated Number of Breast Cancer Cases and Deaths for 2013. 
Approximately 230,000 invasive cases and nearly 40,000 deaths were predicted for 2013. 
These staggering numbers illustrate the need to further develop therapeutic strategies for 
the disease. (Table was adapted from American Cancer Society, 2013) 
Age (Yrs) In Situ Cases Invasive Cases Deaths 
<40 1,900 10,980 1,020 
<50 15,650 48,910 4,780 
50-64 26,770 84,210 11,970 
65+ 22,220 99,220 22,870 
All Ages 64,640 232,340 39,620 
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Figure 1. The Number of Invasive Breast Cancer Cases and Mortality Increases with 
Age. The number of in situ cases increases with age until between the ages of 50 and 64. 
Conversely, there is a decline in the number of cases between the ages of 50 and 64. 
Importantly however, there is an increase in the number of invasive cases and number of 
deaths with age. (Figure was adapted from American Cancer Society, 2013)  
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Figure 2. The Epithelial to Mesenchymal Transition. The EMT has been suggested to 
drive metastasis and stem cell renewal. Molecularly, EMT is characterized by the loss of 
epithelial markers such as e-cadherin, occludin, and claudin, and instead replaced by 
mesenchymal markers such as Snail, Twist, and Slug. (Figure was adapted from C.D. 
Wells, 2015).  
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MATERIALS AND METHODS 
 
Cell line 
MDA-MB-468 cells were passaged at 37o C with 5% CO2 on 10 cm2 dishes in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine 
Serum (FBS) and 5 ml of Penicillin/Streptomycin. Once plates were confluent, growth 
media was aspirated and cells were detached from the plate by adding 1 ml of trypsin 
supplemented with 5 mM ethylenediaminetetraacetic acid (EDTA). After 15 minutes of 
incubation at 37oC, adding 3 ml of complete DMEM quenched the reaction. Cells were 
then split into assay after being spun down at 0.4 x g for 1.5 minutes, re-suspended in 
complete DMEM, and counted on a hematocytometer.  
 
Growth assays 
Growth assays were completed by plating 300,000 cells with, or without, 150 µl 
of a reconstituted, lamin- rich, basement membrane (Matrigel©). Images were acquired 
on the 1500Z Nikon Stereoscope and subjected to colony number and surface area 
analysis using ImageJ64 software. 
 
Viral Transfection 
In 1 ml of serum-free media the following transfection mixture was prepared: 20 
µg of target cDNA,10 µg pRRE and pRSV-REV, and 6 µg VSVG. 25 µl of 
polyethylenimine (PEI) (2 µg/mL) was then added drop wise to the mixture while being 
vortexed at Setting 7. Mixtures were incubated at room temperature for 5 minutes and 
added drop wise to a 10 cm2 plate that was seeded with 4 million 293T cells. Finally, 
 9 
viral media was collected every 24 hours, spun down, and transferred to a new 15 ml 
Falcon© tube. Collection was completed for a total of 48 hours. 
 
Viral Infection  
24 hours prior to viral infection, MDA-MB-468 cells, that were approximately 
95% confluent on a 10 cm2 plate, were trypsinized, spun down at 0.4 x g, and re-seeded 
on 6 cm dishes at a count of 300,000 cells/dish. After 24 hours, growth medium was 
aspirated and dishes were incubated for 8 hours with viral media that was diluted 1:2 in 
complete DMEM. Finally, viral media was aspirated and cells were again cultured in 
complete media for 24 hours at 37oC. 
 
CM037 and Verterporfin Treatment  
MDA-MB-468 cells were split for assay into 6 cm (500,000 cells/dish) or 35 mm 
(300,000 cell/dish) dishes and were treated with Verteporfin, a non-specific YAP-TEAD 
inhibitor, or an ALDH1A1 specific inhibitor, Cynthia Morgan 037 (CM037). Verteporfin 
was obtained from the laboratory of Dr. Clark Wells and CM037 was a gift from Dr. 
Thomas Hurley. Stock solutions of Verteporfin (1 mM) and CM037 (5 mM) were 
initially diluted in dimethyl sulfoxide (DMSO) and stored at -20oC. To standardize 
DMSO concentration (v/v), stock solutions were warmed at room temperature for one 
hour before cell treatment, diluted in DMSO to a target concentration, and finally diluted 
in complete DMEM. For example, Matrigel© growth assays at 20 µM were completed as 
follows. In 35 mm dishes (2 ml assay media/dish), the 5 mM CM037 stock was first 
diluted to 4 mM in DMSO where then 10 µl of the 4 mM solution was raised to 2 ml in 
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complete DMEM and applied to the plate. To control for the concentration of DMSO, a 
separate plate was treated with 10 µl of DMSO standard (Sigma Aldrich) and raised up in 
2 ml of complete DMEM.  
 
Western Blotting 
Protein was purified via RIPA extraction (1 ml/10cm dish) after cells were 
washed 2x with phosphate buffered saline (PBS). After protein extraction, samples were 
incubated on ice for 10 minutes and spun down at 10,000 RPM for 10 minutes at 40C, 
where the supernatant was transferred to a new microcentrifuge tube. Next, a 
bicinchoninic acid (BCA) assay was used to determine the protein concentration of each 
sample. Normalization was completed by diluting each sample in RIPA and 6X loading 
dye. Finally, samples were boiled for 5 min at 950C and 30 µg of protein was loaded into 
each well of a 10% (w/v) sodium dodecyl sulphate-polyacrylamide gel and separated by 
electrophoresis (SDS-PAGE) for 60 minutes at 110V. 
Next, protein was transferred to a nitrocellulose membrane for 1 hour at 24V. 
After transfer was complete, the membrane was blocked in 5% (w/v) milk, washed with 
tris-buffered saline with 0.05% (v/v) Tween-20 (TBST), and incubated overnight in the 
following primary antibodies diluted in TBST: mouse anti-YAP (Abnova, H00010413-
MO1) 1:1000, rabbit anti-pYAP (Cell Signaling, 4911S) 1:1000, and mouse anti-GAPDH 
(Millipore, MAB374) 1:10,000. After primary incubation, the membrane was washed 3x 
for 5 min with TBST and then incubated with a secondary antibody that was either goat 
anti-rabbit Dylight 680 (Thermo-Scientific) or goat anti-mouse Dylight 800 (Thermo-
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Scientific) (1:20,000 in TBST) for 30 minutes where it was then visualized on the 
LiCor©.  
 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Following assay media aspiration and 1x PBS wash, cells were lysed in 0.5 ml of 
Tri Reagent LS, collected in a 1.7 ml microcentrifuge tube, and incubated at room 
temperature for 5 minutes. Ribonucleic acid (RNA) was then extracted by adding 100 µl 
of chloroform and spinning samples down at 13,000 RPM for 10 min at 40C. The 
aqueous supernatant was transferred to a new 1.7 ml microcentrifuge tube and RNA was 
precipitated with an equivalent volume of isopropanol and spun down at 13,000 RPM for 
10 min at 40C. Supernatant was removed and RNA was washed with 500 µl of 75% 
ethanol. Samples were finally spun down at 13,000 RPM for 10 min at 40C, the 
supernatant was removed, and pellets were re-suspended in 20 µl of H2O 
Next, 5 µl of RNA was incubated with: 2 µl of oligo dT (50 uM), 4 µl dNTPs 
(10mM), and 10 µl H2O. After incubation for 5 minutes at 650C, complimentary 
deoxyribonucleic acid (cDNA) was synthesized by incubating the above mixture with: 10 
µl of H2O, 2 µl of reverse transcriptase (RT), and 4 µl of RT Buffer. After 1 hr. at 500C, 
sample concentrations were determined by the NanoDrop© and standardized to 300 ng/µl 
in H2O.   
Finally, 5 µl (300 ng/µl) of cDNA, 10 µl of SYBRGreen, 1 µl (10 uM) of the 
target forward primer, 1 µl (10 uM) of the target reverse primer, and 10 µl of H2O was 
added to each well of the 96-well ABI-FastOpti plate and assayed per the Eppendorf 
RealPlex ABI-FastOpti Protocol. Forward and reverse primers used for this study are as 
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follows: CTGF (AGGAGTGGGTGTGTGACGA/CCAGGCAGTTGGCTCTAATC), 
ALDH1A1 (AGATTGGATCCCCGTGGCGT/TTGACTCCATTGTCGCCAGCAG), 
and GAPDH (GCTCTCTGCTCCTCCTGTTC/ACGACCAAATCCGTTGACTC). 
 
Immunofluorescence 
MDA-MB-468 cells were seeded on 100 µl of Matrigel© in 35 mm MatTek© 
dishes and incubated in assay media per cell culture conditions as described previously. 
After 72 hours of treatment, assay media was aspirated and cells were fixed with 400µl of 
4% paraformaldehyde (PFA) for 20 minutes at room temperature. Cells were then 
washed 3x with 0.5 ml of 1X PBS and permeabilized with 0.5 ml of Triton X-100 (0.5% 
in PBS) for 10 minutes at 40C. After allowing Matrigel© to come to room temperature, 
cells were washed 3x with 0.5 ml of 1X PBS and incubated with 400 µl of blocking 
buffer (0.2g Saponin, 10g BSA, 200 ml 1X PBS) for 60 minutes at room temperature. 
Blocking buffer was then aspirated and samples were incubated with 1 ml of primary 
antibody (mouse anti-YAP, 1:1000 in blocking buffer) overnight at 40C. The following 
day, Matrigel© was again warmed to room temperature and washed 3x with 0.5 ml 
blocking buffer for 5 minutes. Then, samples were incubated with 1 ml of secondary 
antibody (Goat anti-Mouse, Alexa 488, 1:500 in blocking buffer) for 1 hr. in the dark. 
After 3x wash with 0.5 ml blocking buffer, samples were then incubated with 1ml of 
phalloidin toxin covalently coupled to the cruzfluor 560 (1:4000 in blocking buffer) for 
20 min in the dark. Finally, samples were rinsed 3x with 0.5 ml of blocking buffer and 
then incubated with 1 ml of DAPI (Hoechst 1:3000 in blocking buffer) for 7 min in the 
dark, and again rinsed 1x with blocking buffer for 5 minutes. 
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Statistical Analysis  
All statistical analyses were completed using an Independent Samples T test using SPSS 
software Version 22.  
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RESULTS 
 
 
The MDA-MB-468 Cell Line is Sensitive to ALDH1A1 Specific Inhibition in 3D culture 
but not when cultured on plastic. 
Work by the Hurley Laboratory (Indiana University School of Medicine, 
Indianapolis) identified CM037 as a compound that specifically inhibited ALDH1A1, as 
compared to nine ALDH family members, from a high-throughput esterase activity 
screen (C. A. Morgan & T. D. Hurley, 2015). With a Ki value of approximately 0.23 µM, 
and an IC50 value of 4.6 µM, competitive inhibition of ALDH1A1 is achieved by the 
tricyclic ring occupying the hydrophobic pocket formed by Phe171, Val460, and Phe466 
of ALDH1A1. Additionally, this interaction may involve a weak hydrogen bond between 
the carbonyl of the core structure and Cys302 of ALDH1A1. 
The characterization of CM037 provided a platform for the intracellular analysis 
of ALDH1A1 function and Condello et al. was first to demonstrate that selective 
inhibition of ALDH1A1 significantly prevented ovarian spheroid formation (S. Condello 
et al., 2014). Because breast cancer and ovarian cancer have overlapping molecular 
signatures (J. M. Jonsson et al., 2014), we investigated how CM037 would affect the 
phenotype of a triple-negative breast cancer cell line, MDA-MB-468.  
MDA-MB-468 cells were originally derived in 1977 through a pleural effusion 
and are a basal-like, metastatic cell line that lack the estrogen receptor (ER-), 
progesterone receptor (PR-), and the human epidermal growth factor receptor (HER-) (R. 
Cailleau, M. Olive, & Q. V. Cruciger, 1978). The cell line also models therapeutic 
challenges and has been shown to have stem-like properties (S. Samanta et al., 2015). 
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Despite the proliferative potential of the cell line, we were able to effectively attenuate 
cell growth, and do so in a manner that more closely resembles an in vivo status.  
To determine whether inhibition of ALDH1A1 affects the growth of MDA-MB-
468 cells, these cells were plated and cultured as a monolayer on plastic or on Matrigel®, 
before and during treatment with a dose range of CM037. As a monolayer, MDA-MB-
468 cell growth was increasingly inhibited at 50 and 70 µM of CM037 but were 
unaffected by lower concentrations of 10, 20, and 30 µM (Figure 3). However, cells 
plated on Matrigel® showed attenuated growth (>50%) at 10 µM or great concentrations 
of CM037 (Figure 4). This suggested that a concentration of 20 µM of CM037 would be 
effective for subsequent cell based experiments.  
Unpublished data by the Wells lab has shown that when MCF10A cells are 
seeded on Matrigel®, growth is enhanced by endogenous expression of YAP. Further, 
Verteporfin, a compound that disrupts the interaction of YAP with the TEA domain 
(TEAD) transcription factor (E. Felley-Bosco & R. Stahel, 2014), has been shown to 
inhibit the growth of multiple breast cancer cell types including MDA-MB-468 cells. 
This strongly suggests that YAP activity is required for the growth of these cells. As 
summarized in Figure 5A, sensitivity to Verteporfin and CM037 was observed when cells 
were plated on Matrigel® and the combination of the two compounds had a greater effect 
than Verteporfin or CM037 alone (Figure 5B). Additionally, by measuring and plotting 
colony size, or colony number against the time in days, a linear decrease in the number of 
colonies and an exponential increase in colony size can be observed (Figure 5B). Based 
on the results from these growth assays, further investigation into the link between 
ALDH1A1 function and YAP activity was undertaken.  
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Inhibition of ALDH1A1 Affects YAP Signaling in 3D 
The transcription of connective tissue growth factor (CTGF) is directly mediated 
by TEAD and is therefore tightly coupled to YAP activity (J. Avruch et al., 2012). 
Consequently, any effects of ALDH1A1 activity on YAP activity could be measured 
indirectly by measuring the levels of CTGF mRNA transcript. The levels of CTGF 
transcript were therefore monitored in cells treated with CM037 for three days using 
qRT-PCR (See Materials and Methods). As expected, MDA-MB-468 cells cultured as a 
monolayer or in Matrigel® and treated with Verteporfin (1 µM) showed a significant 
decrease in CTGF levels (Figure 6B). However, no significant effect on CTGF transcript 
was observed in MDA-MB-468 cells cultured in 2D, or 3D, upon treatment with CM037 
(Figure 6B). While not statistically significant, cells cultured in Matrigel® showed a 
decrease in mean levels of CTGF transcript (Figure 6B).  
 
Inhibition of ALDH1A1 Promotes Cytosolic Retention of YAP 
Previous work has described that YAP is targeted for degradation in cells 
undergoing stress (D. Pan, 2010). Here, MDA-MB-468 cells cultured as a monolayer and 
treated with CM037 did not show a similar effect (Figure 6A). However, the decrease in 
CTGF transcript in 3D (Figure 6B), while not statistically significant, suggested that 
inhibition of ALDH1A1 might be impacting YAP activity. To determine whether 
inhibition of ALDH1A1 was impacting YAP cellular localization, MDA-MB-468 cells 
were treated for 3 days with CM037 (20 uM) or Verteporfin (0.25 uM) and then fixed for 
analysis by immunofluorescence (See Materials and Methods). As observed in Figure 7, 
cells treated with CM037, showed YAP staining in the cytosol in peri-nuclear punctae, 
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whereas control cells showed a diffuse stain for YAP that was equally distributed 
between the nucleus and the cytosol. These results highlight a potential link between 
YAP inhibition and metabolic stress induced by the inhibition of ALDH1A1. 
 
YAP Activity Correlates with Increased Transcription of ALDH1A1 
Recent work has suggested that the expression of ALDH1A1 (H. Q. Duong et al., 
2012), and the binding of YAP to TEAD4, is important for the chemoresistant phenotype 
(Y. Xia, Y. L. Zhang, C. Yu, T. Chang, & H. Y. Fan, 2014). Based on this information, 
and data acquired from our qRT-PCR analyses, we wondered if the transcription of 
ALDH1A1 is regulated by YAP activated TEAD4. I therefore analyzed whether any 
TEAD family transcription factors had been reported to bind in the promoter of any of 
the ALDH genes in the chromatin immunoprecipitation (ChIP) data from the University 
of California Santa Cruz (UCSC). This revealed that TEAD4 has been shown to 
precipitate multiple fragments of the promoter of the ALDH1A1 gene (Table 1 and Table 
2). While TEAD was also observed to bind five other ALDH genes, generally it was 
highly enriched for binding ALDH1A1. This strongly suggested that YAP activation 
might promote the expression of ALDH1A1.  
To explore the possibility that YAP may induce ALDH1A1 transcription, MDA-
MB-468 cells were stably infected (See Materials and Methods) with either wild-type 
YAP, or red fluorescent protein (RFP) and treated with CM037 (20 µM) or Verteporfin 
(0.25 µM). As shown in Figure 8, overexpression of wild-type YAP led to a significant (p 
< 0.001) increase in ALDH1A1 expression, which was significantly (p < 0.001) reduced 
when cells were treated CM037, or Verteporfin. Based on these results, it is concluded 
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that YAP activity drives ALDH1A1 expression whereas ALDH1A1 function is required 
for YAP activity.  
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Figure 3. Specific Inhibition of ALDH1A1 Does Not Affect Cell Growth in 2D. 
Specifically inhibiting ALDH1A1 did not dramatically affect cell growth when MDA-
MB-468 cells are cultured as a monolayer. Based on this result, it was reasonable to 
conclude that ALDH1A1 is not required for growth in 2D. 
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Figure 4. MDA-MB-468 Cells are Sensitive to Inhibition of ALDH1A1 in 3D Culture. 
When MDA-MB-468 cells were cultured on a lamin-rich reconstituted basement 
membrane (Matrigel®), and treated with CM037, the ALDH1A1 specific inhibitor, 
growth attenuation was observed. From this, it was postulated that ALDH1A1 activity 
was tuned by a mechansim sensitive to microenvironment changes, such as YAP. 
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Figure 5. Inhibition of ALDH1A1 Attenuates MDA-MB-468 Growth in 3D Culture. 
A) Response to ALDH1A1 inhibition was unremarkable when MDA-MB-468 cells were 
cultured as a monolayer (upper panel). However, growth inhibition was acquired when 
cells were cultured in Matrigel®, a lamin-rich, basement membrane. This result indicated 
that ALDH1A1 activity could be correlated with signaling cascades sensitive to the 
extracellular environment. B) To delineate whether ALDH1A1 inhibition affected 
growth, or migration, pixel density analysis of colony number and size was used (See 
Materials and Methods). As shown above, the exponential growth in colony size was 
attenuated when cells were treated with CM037 (20 uM), Verteporfin (1 uM), or both. 
Compared to colony number however, the differences between treatment groups were 
unremarkable, suggesting that ALDH1A1 inhibition was affecting growth and not 
migration.  
  
 22 
 
Figure 6. Inhibition of ALDH1A1 Affects YAP Signaling. A) Based on Western blot 
and pixel density analysis, it is reasonable to propose that as a monolayer, MDA-MB-468 
cells do not respond to ALDH1A1 inhibition by phosphorylating YAP or modifying the 
amount of YAP protein. B) Conversely, when MDA-MB-468 cell are cultured in 
Matrigel®, there is a significant reduction in YAP nuclear activity, as measured by the 
fold change in CTGF transcript. Together, these results suggest that YAP activity and 
ALDH1A1 function are not mutually exclusive. 
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Figure 7. Inhibition of ALDH1A1 facilitates cytosolic retention of YAP. Previous 
work has demonstrated that YAP can be retained in the cytosol and targeted for 
degradation under metabolic stress. In this investigation, when MDA-MB-468 cells were 
cultured in Marigel© and treated with CM037, YAP was localized in the cytosol. These 
findings correlate with the growth assays and changes in CTGF, and ALDH1A1, 
transcription, indicating that the inhibition of ALDH1A1 is a form of cellular stress that 
prevents YAP nuclear localization. 
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Table 2. ALDH Isoenzyme Characterization. The ALDH isoenzyme family consists of 
19 isoenzymes, each with a distinct coding region, function and cellular localization. 
Expression of ALDH1A1, or ALDH3A1, has been implicated as a marker for cancer 
stem cells but the functionality of the enzymes remains to be elucidated. TEADs have 
been more thoroughly defined in regards to embryonic development and bind to coding 
regions of ALDH1A1, ALDH1A2, ALDH2, ALDH4A1, and ALDH5A1. Based on this 
information, it is reasonable to conclude that YAP could drive expression of the TEAD-
containing ALDHs. 
Human 
Gene Coding Region Position 
Implicated in 
Stem Cells 
TEAD 
Element  
ALDH1A1 chr9:75,516,124-75,567,916 Yes YES  
ALDH1A2  chr15:58,247,395-58,357,848 No YES  
ALDH1A3 chr15:101,420,113-101,454,978 No No 
ALDH1B1 chr9:38,395,746-38,397,299 No No 
ALDH1L1 chr3:125,822,634-125,899,811 No No 
ALDH1L2 chr12:105,418,202-105,478,214 No No 
ALDH2 chr12:112,204,787-112,247,379 No YES 
ALDH3A1 chr17:19,641,534-19,648,442 Yes No 
ALDH3A2 chr17:19,552,285-19,576,547 No YES 
ALDH3B1 chr11:67,782,768-67,795,406 No No 
ALDH3B2 chr11:67,430,686-67,434,406 No No 
ALDH4A1 chr1:19,199,339-19,229,017 No YES 
ALDH5A1 chr6:24,495,225-24,533,940 No YES 
ALDH6A1 chr14:74,527,345-74,551,097 No No 
ALDH7A1 chr5:125,880,657-125,930,890 No No 
ALDH8A1 chr6:135,239,553-135,271,191 No No 
ALDH9A1 chr1:165,632,287-165,667,795 No No 
ALDH16A1 chr19:49,963,102-49,973,724 No No 
ALDH18A1 chr10:97,366,519-97,397,163 No No 
 
  
 25 
Table 3. TEAD Response Elements in the ALDH Isoenzymes. Further analysis of the 
ALDH genes indicates that TEAD binds to multiple regions of particular ALDH genes, 
suggesting that the expression of TEAD-containing ALDHs is differentially regulated.  
Human 
Gene TEAD Position 1 TEAD Position 2 
TEAD 
Position 3 
ALDH1A1 
chr9:75562768-
75563207 chr9:75549119-75549558 
 
ALDH1A2 
chr15:58306274-
58306588 chr15:58357920-58358283 
 
ALDH2 
chr12:112204502-
112204751 
chr12:112212050-
112212252 
 
ALDH3A2 
chr17:19563703-
19564009 
  
ALDH4A1 
chr1:19228972-
19229221 chr1:19221937-19222300 
chr1:192106
36-19210999 
ALDH5A1 
chr6:24504872-
24505510 
   
  
 26 
 
Figure 8. Overexpression of YAP Correlates with an Increase in ALDH1A1 
Expression. By overexpressing YAP and promoting cell growth, the expression of 
ALDH1A1 increased significantly. Additionally, by treating cells with CM037 or 
Verteporfin, the increase in transcription of ALDH1A1 was attenuated. Together, these 
results demonstrate a novel link between YAP activity and the expression of ALDH1A1. 
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DISCUSSION 	  
Anatomically, the highly specialized epithelia, specifically the luminal and 
myoepithelial cells, maintain a highly ordered architecture that dictates the function of 
the tissue (T. Gudjonsson, M. C. Adriance, M. D. Sternlicht, O. W. Petersen, & M. J. 
Bissell, 2005). These cells have been shown to be sensitive to changes in the composition 
of the underlying stroma and are implicated as structural tumor suppressors of the breast 
tissue (T. Gudjonsson et al., 2002). However, cancerous cells have altered responses to 
said regulation (D. Hanahan & R. A. Weinberg, 2011) which facilitates their aberrant  
growth and progression (M. W. Pickup, J. K. Mouw, & V. M. Weaver, 2014). 
Furthermore, pro-growth signaling can be altered by culture conditions that more closely 
reflect an in vivo status (M. W. Pickup et al., 2014). Consistently, we observed a dramatic 
increase in the potency of inhibition of the rapid proliferation of MDA-MB-468 cells by 
CM037 when cells were cultured in Matrigel© versus on plastic (Figure 4). Thus, the 
Matrigel© microenvironment is proposed to increase the dependence of these cells on 
YAP for their growth, which in turn makes them more sensitive to metabolic stresses 
induced by inhibiting ALDH1A1. In regards to tumor progression and applicability to 
patient outcomes, this suggests that as breast cancer progress into a more invasive form 
that presumably has a higher population of mesenchymal cells, they may become more 
sensitive to treatment with CM037. 
As tumors progress and occupy more space, vasculature and other means of 
nutrient acquisition become limited, and cells sustain limitless replicative potential by 
alternative means (D. Hanahan & R. A. Weinberg, 2011). In this regard, Otto Warburg 
was first to postulate that cancer cells preferentially metabolize glucose through 
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glycolysis instead of the more efficient pathway, oxidative phosphorylation, even in the 
presence of oxygen (C. R. Justus, E. J. Sanderlin, & L. V. Yang, 2015; O. Warburg, 
1956a, 1956b; O. Warburg, F. Wind, & E. Negelein, 1927). However, the by-products, 
mainly aldehydes and reactive oxygen species (ROS), of such a stressed metabolic state 
are toxic to the cells and therefore must be metabolized appropriately. ALDHs have 
already been characterized as mediators of cell detoxification (G. Muzio, M. Maggiora, 
E. Paiuzzi, M. Oraldi, & R. A. Canuto, 2012) and in particular, ALDH1A1 has been 
summarized to mediate the detoxification of oxazaphosphorine anticancer drugs as well 
as lipid peroxidation products (D. P. Agarwal, U. von Eitzen, D. Meier-Tackmann, & H. 
W. Goedde, 1995; N. E. Sladek, 1999). Based on our results, and the assumption that 
YAP is inducing a vulnerability to metabolic stress, it can be theorized that therapeutic 
intervention of CM037 exacerbates metabolic stress beyond a capacity that cells can 
handle and thus prevents breast cancer stem cells from utilizing stromal changes to 
facilitate YAP-mediated growth and transcription of stem-like genes, such as ALDH1A1. 
Additional experimentation would be needed to validate this idea and to define the 
mechanism by which this occurs. However, an analysis of the literature suggests a model 
described in the proceeding paragraph. 
The AMP-activated protein kinase (AMPK) is a serine/threonine kinase (Ser/Thr) 
that is sensitive to cellular energy levels and is activated by changes in AMP:ATP, and 
ADP:ATP, ratios (D. Carling & B. Viollet, 2015). AMPK phosphorylates several 
substrates and recent work has shown that AMPK phosphorylates YAP in response to 
cellular energy stress (J. S. Mo et al., 2015). Additionally, liver kinase B1 (LKB1), which 
independently regulates AMPK activity via phosphorylation of Thr172 (D. Carling & B. 
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Viollet, 2015), also has been shown to regulate YAP through cytosolic retention post 
phosphorylation at Ser127 (H. B. Nguyen, J. T. Babcock, C. D. Wells, & L. A. Quilliam, 
2013). Based on this information, one could postulate that the decrease in YAP activity 
(Figure 6 and Figure 8), and YAP cellular localization (Figure 7), is facilitated by YAP 
phosphorylation by either AMPK or LKB1. In order to test this hypothesis, co-
immunoprecipitation assays of YAP and AMPK, or LKB1, and immunoblotting of 
phosphorylated YAP would be completed. Additionally, one should consider the 
potential impact of conversion of RA by ALDH1A1 and the consequent reduction in its 
levels that are available to promote RAR dependent gene expression that promotes 
cellular differentiation. 
 Canonically, RA promotes embryonic gene expression by binding to the nuclear 
retinoic acid receptor (RAR) (M. Petkovich, N. J. Brand, A. Krust, & P. Chambon, 1987) 
and facilitating the formation of the retinoid X receptor (RXR) and RAR heterodimer. 
The RAR-RXR complex then recognizes RA response elements (RARE) within the 
genome to coordinate gene expression (G. Duester, 2008). Independently of ligand 
presence (P. Germain et al., 2006), the RXR has also been shown to form a heterodimer 
with the peroxisome proliferator-activated receptor (PPAR) (S. A. Kliewer, K. Umesono, 
D. J. Noonan, R. A. Heyman, & R. M. Evans, 1992), which results in transcription of 
genes involved in cell metabolism (T. Varga, Z. Czimmerer, & L. Nagy, 2011; J. M. Way 
et al., 2001). In this context, it could be hypothesized that CM037 treatment, which 
inhibits formation of RA, triggers a nutrient recycling event where a metabolic flux is 
enhanced by RXR binding to PPAR, instead of RAR. It would therefore be potentially 
interesting to test whether ALDH1A1 inhibition or YAP activation in MDA-MB-468 
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cells alters the formation of the RXR-PPAR complex. If so, this would suggest a new 
mechanism by which the basal-like phenotype in MDA-MB-468 cells is driven by their 
expression of ALDH1A1 
As previously stated, YAP could be inactivated through phosphorylation by 
AMPK or LKB1, in response to ALDH1A1 inhibition. However, this claim could be 
invalid if we were unable to clearly demonstrate that CM037 treatment is a metabolic 
stress. To test the degree to which this compound induces metabolic stress, one could 
measure the ratio of NAD/NADH in control cells or cells treated with CM037. If cells are 
highly stressed it would be predicted that NAD+ will accumulate in excess over NADH. 
This could be further explored through a more complete characterization of the metabolic 
profile of these cells using the Seahorse assay, which would allow the determination of 
whether treatment with CM037 altered the extracellular acidification rate (ECAR) and/or 
oxygen consumption rate (OCR). Basal metabolism would be predicted to be glycolytic, 
whereas cells treated with CM037 and/or Verteporfin may have reduced glycolytic 
potential. If the NAD/NADPH and Seahorse assays demonstrate that metabolic stress is 
induced by CM037 treatment, then a novel mechanism by which YAP and ALDH1A1 
are regulated could be proposed. Furthermore, results from these assays could provide 
novel support for directing therapies towards cancer metabolism. 
Overall, there is a lack of demonstrated efficacy of new therapies against triple-
negative breast cancer (E. Andreopoulou, S. J. Schweber, J. A. Sparano, & H. M. 
McDaid, 2015). For instance, the ineffectiveness of adjuvant therapies still remains a 
concern. For example, the inhibitor of the mammalian target of rapamycin (mTOR), 
everolimus (M. Yunokawa et al., 2012), and the anti-vascular endothelial growth factor 
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(aVEGF) monoclonal antibody, bevacizumab (K. Miller et al., 2007) failed to improve 
primary clinical outcomes such as progression-free survival. However, the work in this 
thesis, suggests a novel paradigm for treatments centered around the YAP/ALDH1A1 
axis (Figures 5 and 8) that might be effective in the least treatable phase of the disease 
involving metastatic breast cancer. To this end, a xenograft transplant model could be 
proposed, where mice would be injected with MDA-MB-468, or patient-derived cells, 
and treated with, or without, CM037. To assess the efficacy of the compound overall 
survival, tumor grade, and rate of metastasis would be measured. This might extend our 
observations (Figures 3, 4, and 5) by showing that inhibition of ALDH1A1 impacts real 
tumor development  
 Overall, several outstanding questions remain. For instance, because cancer cells 
utilize various biochemical and molecular alternatives to promote growth and 
proliferation, there is the potential that the phenotype observed upon ALDH1A1 
inhibition was propagated by another mechanism, or pathway, separate from inactivation 
of YAP such as through PPAR-RXR formation. Further, because we did not directly test 
total ALDH activity, it is not clear whether overall metabolism of aldehydes is being 
impacted by treatment with CM037 or whether there is a specific impact of ALDH1A1 
inhibition. Another question is how the overexpression of YAP drives the transcription of 
the ALDH genes that have been shown to have TEAD4 binding within the gene. 
Furthermore, what is the role of activating a profile of ALDH1 genes versus ALDH1A1?  
Given our specific effects with CM037, it seems likely that ALDH1A1 is playing a 
critical role that may be complemented by expression of the other ALDH isoforms. 
Further, how important is the induction of the ALDH isoforms by YAP attributed to 
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establishing the metabolic profile of cancer stem cells? The answers to these questions 
will ultimately indicate whether treatment with CM037 will be a viable alternative for 
clinical studies testing its real therapeutic potential (Figure 9). 
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Figure 9. Proposed Model for CM037 Inhibition of the YAP-Mediated Stem Cell 
Phenotype. Based on the data collected in this study, there is reasonable evidence to 
conclude that stem-cell phenotype is facilitated by YAP nuclear localization where genes 
such as ALDH1A1 are up regulated. However, the stem-cell phenotype, which is thought 
to contribute to metastasis and recurrence, could be targeted by therapeutic administration 
of CM037.   
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